Business
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
Results Support TAMP’s Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-DeliveryMOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that new clinical data will be presente
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIkpg_5WC5Ht6PAvrhd3Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"Results Support TAMP’s Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-Delivery","length":174,"tagName":"p"},{"type":"text","content":"MOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that new clinical data will be presented at the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting on February 6, 2026.","length":427,"tagName":"p"},{"type":"text","content":"The clinical data abstract entitled, “Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors,” was led by Christopher Laing, MD of Sutter Health in California. The study explores a simplified method for measuring intra-arterial pressure during procedures that use the TAMP (Trans-Arterial Micro-Perfusion) therapy platform enabled by the RenovoCath catheter, an adjustable, double-balloon drug-delivery device, and how these measurements along with other variables can play a role in optimizing targeted delivery of chemotherapy in difficult-to-treat tumors.","length":662,"tagName":"p"},{"type":"text","content":"“The ability to measure intra-arterial pressure in real-time provides valuable insight into the mechanics of the approach during TAMP procedures,” said Dr. Laing, MD. “As these techniques are further validated, pressure monitoring has the potential to help clinicians better understand and refine the variables that influence effective drug-delivery.”","length":351,"tagName":"p"},{"type":"image","alt":"Illustration of T...